Pod Insights Pharmacy Podcast Network Lies and Lawsuits | Essential: The Pharmacy Compounding Podcast About this episode In this edition of Essential, we look at how we’re pushing back against the FDA’s upcoming ban on desiccated thyroid extract, why drugmakers’ latest tactics against compounding pharmacies are backfiring, and we give you a great way to make sure your practice is performing at its best. Then we take a deep dive with attorney and pharmacist Mark Boesen into the lawsuits being filed against compounding pharmacies, what the results have been, and how they might affect more than just pharmacy in the future. Boesen & Snow Law: https://www.boesensnowlaw.com/ DTE story (https://a4pc.org/news/ask-your-patients-help-us-protect-dte-access) “FDA’s confusing warning letters” (https://a4pc.org/news/fdas-confusing-warning-letters) “FDA’s green list: Not our problem?” (https://a4pc.org/news/fdas-green-list-not-our-problem) Compounding.com/thyroid Best practices documents (a4pc.org/bestpractices) National Review article on FDA crackdown (https://archive.ph/LYy7t)
Transcript 0:05 Speaker 00 You are listening to the global network of podcasters dedicated to the pharmacy profession. Welcome to the pharmacy podcast network.
0:24 Speaker 01 Welcome to Essential, the pharmacy compounding podcast with the latest news and analysis from you know it, the Alliance for Pharmacy Compounding, the voice for compounding pharmacy. I'm your host, Andrew Cantor, and today we've got a follow up on the desiccated thyroid extract story, what drug makers battalion of lawyers are up to, and why it backfired, and more. Then we'll dive into some of the latest court cases against compounders with a lawyer who's kind of an expert at representing compounding pharmacies. But first, let's do that news.
1:05 Speaker 01 We want to start with a quick follow up to the big story we covered in our last podcast. That's when we talked about how the FDA is reclassifying desiccated thyroid extract, DTE, as a biologic. And that means it'll be out of bounds for compounding, and therefore out of bounds for many, many patients. And that's supposed to take effect next August. Now, last time, we talked about why the decision was so wrong on a lot of levels. The biggest issue, though, is that it's going to be a real problem for patients. A lot of the people who need thyroid meds just can't take the synthetic stuff. And that means that in a year, they're going to be out of luck. APC is obviously concerned about this. Protecting those patients is actually one of our top priorities at the moment. Here's what we're
1:49 Speaker 01 thinking. It's going to take a two-pronged approach to get the FDA to change its mind. First, we need to put some pressure on the agency directly. APC is doing that, obviously, but boy, would it help if patients and prescribers did too. I mean, at least in theory, these are the people the FDA is there for, right? Second, we need to reach out to Congress to get it to intervene. Again, APC is doing that. We've got lobbyists in Washington. But again, it would help a lot to have patients and prescribers reach out to their senators and representatives. So here's what we did. We created a webpage. It's compounding.com/thyroid. And that's also in the show notes. On the page, there are four big buttons, two for patients, two for prescribers.
2:34 Speaker 01 One button will let them send a message to the FDA. The other one will let them send a message to their members of Congress. And it really is just about that simple. We've got sample letters. We handle the sending. And there's even a way to leave a written or video testimonial about DTE. Anyway, it's all on, once again, compounding.com/thyroid. The whole point is to ramp up pressure on the FDA and get it to realize it's mistaken and leave DTE alone.
3:04 Speaker 01 All right, let's talk about the newest games drug makers are playing. They really do not like compounding, do they? So their latest tactic, spread the idea that somehow compounders are using low quality ingredients in their drugs. What they've done is create fake organizations with legitimate sounding names. They're supposed to sound like some kind of independent organization on a mission of righteousness. But it's just a sock puppet stuffed with drug maker dollars. These sock puppets, they send out these fake independent press releases. And those releases just happen to parrot the same lies as the pharma companies. Like, can we say lies? No? False claims? Okay, false claims. Okay, so even if people don't fall for the false claims,
3:50 Speaker 01 the drug makers hope to confuse regulators, confuse the media, because the more confusion, the more scared patients will be. But sometimes those plans backfire, at least a little. Here's the story. Through one of those sock puppet groups a few months ago, drug makers claimed that shipments of counterfeit GLP-1s came into the US from who knows where. They came in with stickers or whatever that said they were bound for compounding pharmacies. Yeah, we all know there are fake drugs and other illicit substances coming into the US, and that's a problem. But the notion that these were going to compounding pharmacies, legitimate compounding pharmacies, it's nonsense. First off, who the heck cares what some shady company from across the Pacific puts on its drugs? They could say for delivery to Buffalo,
4:35 Speaker 01 New York, but it doesn't mean Josh Allen is getting into the GLP-1 business. But the bigger thing is, compounding pharmacies don't get their ingredients directly from manufacturers. All right, yeah, there are some edge cases, but by and large, compounding pharmacies source their ingredients from FDA-registered American wholesalers who have gotten them from FDA-registered manufacturers. And the wholesalers, they analyze the ingredients before they sell them to the pharmacies. And heck, most of them even do independent third-party testing. The point is, no licensed compounding pharmacy is buying ingredients off some random ship docked in Los Angeles or wherever it was. But still, the drug makers, sock puppets, make a lot of noise and make a
5:16 Speaker 01 lot of false claims without any evidence to back it up. And still, it got the attention of some folks in Congress. Not all of them understand how the compounding supply chain actually works. See, this is what I was talking about, about spreading confusion. So some members of Congress pushed the FDA to do something about this nonexistent problem. What the FDA did was take its list of legitimate GLP-1 manufacturers, the ones that it knew met all its standards, and named it the Green List. APIs from anywhere else it said were going to be confiscated. The drug makers, they were hoping this would be some big news story, I don't know, scare people away from compounders. The problem was, it didn't affect compounding
5:58 Speaker 01 pharmacies at all, not the legit ones, anyway, because the manufacturers on the Green List are exactly the ones the wholesalers were already using. So the Green List story comes out, and it doesn't take long for journalists to realize it's pretty much a non-story. And yes, APC can't take a little credit for helping explain that. If anything, and here's where it kind of backfires, the FDA actually validated that compounding pharmacies were indeed following the rules, using the same kinds of high-quality ingredients that the big drug makers were, at the Green List to prove it. So who does that Green List actually affect? Illegal pop-up shops, you know, the ones selling the do-it-yourself GLP-1 injections on TikTok or whatever? And honestly, those folks deserve what's coming to them.
6:44 Speaker 01 There's another recent development in the pharmacy world. You've probably heard at least the general story. The FDA was ordered to crack down on misleading claims in direct to consumer drug ads, and that included everyone from big pharma companies to compounders to telehealth platforms, everyone in between. I'm not going to talk about the letters that went to Eli Lilly or Novo Nordisk or any of those. This is a compounding podcast. The kinds of letters we've heard that were sent to compounders, they definitely raise some eyebrows. Apparently, one of the claims that some compounders made, claims the FDA had a problem with, was that the active ingredient in their compounded GLP-1 was the same as that in a commercial GLP-1. Now FDA says that's deceptive. So think about that for
7:29 Speaker 01 a second. The FDA says it's misleading for compounders to point out that their active ingredient is the same as the one in Ozempic or Zepbound or Wegovy or whatever. But it is the same ingredient. It has to be the same. If it wasn't, they wouldn't be allowed to compound with it. The law is crystal clear about that. But saying so that's misleading? It's like the FDA tripped over its own logic rushing to get those letters out. The National Law Review has a great article about the whole mess and the weird penalty flags the FDA's been throwing. There's a link to the article in the show notes. Oh, as a side note, by the way, remember that the same FDA crackdown is also affecting the big drug makers. We
8:10 Speaker 01 love the story about AstraZeneca being told to take down an ad because it had teenagers discussing drugs and there wasn't an adult in the room. Sauce for the gander, you might say.
8:24 Speaker 01 All right, enough about GLP-1s for a moment. Every now and then, APC releases what we call a best practices document. It's a short guide. It's written by a panel of experts and it covers one of the important issues that's been cropping up with our members. We've got some on specific topics, but our latest is a little different. It's a bit broader. It's called Best Practices for Dispensing Compounded Therapies, and it is as broad as that title implies. It pretty much covers all the basics of compounding, packaging, labeling, logistics, dealing with adverse reactions, handling recalls, counseling patients. Yeah, I said it was broad. And no, it's not telling you how to do your job. It's like a refresher.
9:06 Speaker 01 I mean, let's face it, you do something long enough and it kind of becomes automatic. So we think it's a good idea to take a moment and stop being automatic. Just download the document. It's free. The link is in the show notes. See how what you do compares to the best practices. Chances are you're right on the money, but you never know. And if nothing else, it's a chance to talk to your team about how you all work together. So grab it. And while you're there, take a look at the other best practices docs we have. There's good stuff there and some of it is worth copying and pasting into your own pharmacy SOP manual.
9:41 Speaker 01 And now it's time for our deep dive. Today we're going to look at lawsuits. In particular, some of the suits that have been filed by the big drug makers against compounding pharmacies and telehealth platforms. They haven't really been terribly successful. Just recently, there was a, there was one against Willow Health. That got thrown out. There was one against Stri Pharmacy in Arizona. That was also dismissed. Yeah, it was on a technicality, but still dismissed. And there's one still going on against Moshi Health in Southern California. But the judge in that case doesn't seem terribly sympathetic toward Eli Lilly. And you know what they say.
10:24 Speaker 01 All right, maybe not out because this is the American legal system and they can refile. But lately at least they've been swinging and missing. So here to discuss them and a few other lawsuits, we have Mark Boson, one of the founding partners of Boson and Snow Law in Washington DC. Not only does Mark specialize in pharmacy law, he's actually a practicing pharmacist. And that is not a combination you see a lot of. And joining Mark is APC CEO Scott Bruner, who, like anyone with a lawyer as a captive audience, has a lot of questions. So Scott, Mark, take it away.
11:01 Speaker 02 Lots of questions, Andrew. Thank you. And Mark, welcome. This is a hot topic, and we're looking forward to hearing some of your thoughts about what is truly a slew of litigations. We're not even going to talk about cease and desist letters. Of course, the drug makers continue to send those out not only to compounding pharmacies, but also to some prescribers, providers, which I think was a bit jarring for some of those. But we're going to talk about litigation, and that trio of lawsuits that Andrew has mentioned is where I'd like to start. It strikes me, and I'd be interested in what
11:43 Speaker 02 you think about this. It seems unusual, out of the ordinary, maybe, for judges to, and this is my word, but editorialize the way they have in these three cases, Willow, the Strive case, and the Moshi case. The judges have seemed remarkably unsympathetic to some of Lilly's claims. In one of those cases, the judge asked one of the Lilly lawyers a question. The lawyer answered at length, and the judge responded by saying, "What I hear you saying is you don't have anything." How unusual is it for judges to do this?
12:23 Speaker 02 Because in each of those three cases, what the judges are saying really validates that compounding pharmacies are working within law and policy to serve patients with compounded GLP-1 drugs.
12:35 Speaker 03 That's a good question, Scott. And it is a little unusual regarding the volume of information that the courts are putting in with their decisions, particularly in a decision that happened in the Strive case the host talked about, Andrew talked about. Strive was dismissed on a technicality. What was that technicality? Very simply, the court said, "Hey, Delaware isn't the right place to sue this entity. This entity's primary place of business is in Arizona." And your allegation that they have a website, that they have... A non-resident pharmacy permit in Delaware and that people in Delaware buy your products makes it a legitimate venue to utilize the Delaware courts wasn't good enough, not in
13:20 Speaker 03 2025, when every major business has a website and advertises to people all over the country. It doesn't mean that they have what's called personal jurisdiction, subject themselves to the courts of the other states. If they don't have any brick and mortar there, they don't have any employees there, they don't have any substantial business there. And that's what the Delaware court did. And it would have been very easy for that judge to simply rule on that personal jurisdiction issue. Does the Delaware court have personal jurisdiction over this entity that is headquartered in Arizona? And it could have been a very, very short holding, but it wasn't. It was several pages long. And that narrative, there's a
14:02 Speaker 03 term for it in the legal industry, we call it dicta, D-I-C-T-A. Judges have the discretion to write dicta. And dicta is simply a commentary that has no bearing or no legal precedence on what's next. It's just a way for the judge to say, hey, I did review some of this case. I needed to in order to evaluate personal jurisdiction. And so I do have an opinion about the merits. And although it might be inappropriate for the judge to write about the merits of the case in a dismissal on personal jurisdiction, it's within their discretion to do so. And they usually do that when they have strong opinions about
14:44 Speaker 03 what's happening next. And one of my favorite lines in that decision from that judge in Delaware, and it's the first couple of sentences, and it was very clever, and it read something like, and I'm paraphrasing, "The federal courts reward drug innovation, but it does not reward innovative thoughts about jurisdiction." Eli Lilly's pleading has both, which is, hey, you're a drug innovator, we applaud you for that, but we don't appreciate you trying to be clever and innovate a new theory about personal jurisdiction. And so we're going to send this out of this jurisdiction. And they're free.
15:28 Speaker 03 Lilly's free to refile in another jurisdiction. We expect it to be Arizona because that would be the clearest place for them to refile. And so we'll wait and see. But that judge was very critical, as were the Willow judge, as were the Mochi judges in their interrogation of the lawyers for Eli Lilly. In Willow, what was remarkable, and in Mochi, what was remarkable, was they did talk about the merits. And the merits are simply this. One is, was there false or misleading advertising? And that's what Andrew was talking about.
16:10 Speaker 03 And there's tremendous skepticism that there was anything false or misleading about the advertising that these defendants are being accused of. But more importantly, even if you have an injustice, even if you're harmed by the legal system, you have to have an injury for the court to fix. So what the judges are all forecasting is, even if I can get you to the point where you've approved, you know, you've proved some false or misleading advertising, help me explain what your injury was. And in Mochi's hearing, the judge was very concerned that there was no injury here. In Willow, the judge says there's no injury here. And that makes sense.
16:55 Speaker 03 You can't simultaneously tell the shareholders of the publicly traded companies that we're selling as much drug as we can, as fast as we can, and especially during a shortage period, we don't have enough to sell. But we were also injured because these compounding pharmacies were supplementing the market with more drug. Which one's the fact? Did you have enough drug to sell everybody? Or based upon the information you provided to the FDA and exists in real life, that people couldn't find this drug at their pharmacy? What damage did you have? If you're selling 100% of the product that's coming off of your assembly line, help me
17:40 Speaker 03 understand what damage there was. And that's the big hurdle that Eli Lilly's lawyers are just having a tough time explaining.
17:49 Speaker 02 Yeah, it is fascinating. In the Willa case in particular, the judges, and I've learned a new word, thank you, Mark, dicta. The judge found that personalized, supervised, compounded prescriptions are indeed lawful, even made a comment that seemed to me to be sort of a swipe against the claims that Eli Lilly had made, that the entity was engaged in mass production, mass manufacturing of compounded drugs. And the judge said, basically, in effect, just because something is produced in volume doesn't mean that it is not intended for an N of one, for an individual patient and the needs of that individual patient based on a prescriber.
18:34 Speaker 02 So, let me ask, and of course, I'm asking you to speculate, do you see these as indicative of how other courts might react? Again, Lilly is able to adjust, I guess, its claims, to come back with a different set of claims in these. Certainly, they're going to, they are likely to pursue the Strive case in a different jurisdiction. Do you think there's more of the same? Or are these just three sympathetic judges that Lilly happened to draw?
19:09 Speaker 03 I don't think it's three sympathetic judges that Lilly accidentally drew. I don't think there's a coincidence here. And why, and this is the basis of, why do we seek out different courts? Why did Lilly go to Delaware in the first place, is a question to ask yourself. Eli Lilly itself is in the Southern District of Indiana. That's their home turf. That's where they usually file cases, because that's where they employ many, many Indians, and they're a big deal there. They might have avoided Arizona, because that's where Strive is. And there's a perception we learn in law school, that if you can avoid fighting the
19:53 Speaker 03 other side in their home territory, try not to. Because regardless... Regardless of the blindfold that's on Lady Justice, there's always a bias of, "Well, this is an employer. These are people that might be friends and neighbors of mine." There's this bias, whether it's conscious or not, that's there. And so you try to find people in a neutral environment. And so Delaware would be neutral to both Eli Lilly and Strive. And Delaware is notorious for being a very neutral environment. They have very business-friendly laws there. Lots and lots of businesses choose to organize there and choose those courts because
20:36 Speaker 03 those judges are known and have a reputation, and it's a proud reputation, of being unbiased, very critical thinkers, and they don't choose sides. And so you've got a Delaware judge, who not only dismissed the case because he found no jurisdiction, but wrote a tremendous round of dicta supporting Eli, supporting Strive's position. And then you've got another judge on the other side of the country, in Mochi, in the San Francisco courts. The Ninth Circuit, which is where I live and I practice most, is notoriously difficult to predict.
21:16 Speaker 03 And it's because it's such a large district. Geographically, it is the largest district in the United States. So many states, from the most liberal states to the most red states, all sit in the Ninth District. And when you see a Delaware, and so we always perceive, particularly the San Francisco courts, as to have a much different culture. They tend to be more liberal. They tend to be more activist. They tend to be reviewing things that may not fit neatly within statutes and regulations, and we accuse them sometimes of inventing new law. But that judge didn't want to do that there, despite the reputation
21:58 Speaker 03 of her own circuit, of her own city, of her own brethren. She is taking a very, very critical view, just like the Delaware judge did. So you've got two very, very different cultures of jurists. And then, in the Willow case, you've got some consistency.
22:16 Speaker 03 It is not a coincidence that they found the three judges that are gonna, that all have taken the position that they have grave concerns about the strength of Eli Lilly's case. Because it is difficult. You talked about it, Andrew talked about, when, when, I said it early on when they filed, when Lilly filed its claim against Mochi and Willow. When they started picking on the use of personalization, I said, well, that's the definition of compounding. We're personalizing a dose. And I'm glad you brought up the, just because there are hundreds of patients, or thousands
23:01 Speaker 03 of patients, or even 10,000s of patients, that need a personalized dose that happens to be the same as the other 9,000 people, doesn't mean that it's not personalized. This is a drug that the Kaiser Family Foundation tells us that likely 1 in 8 American adults is on now or has taken, and that's probably a conservative estimate because there's no way for them to count how many compounds are being dispensed. It's probably a little higher than that. Right. And so you've got tens of millions of people out there, tens of millions of doses that are going out there every year between Novo's drug, Lilly's drugs, and the compounders' drugs.
23:43 Speaker 03 And if 10,000 or even 100,000 of those millions of doses need to be the same for a handful of people, well, that makes sense. You've got, you've got a number of patients that share the same need for something that's clinically different, provides a substantial benefit to the patient, that the FDA-approved drugs don't do. And, and my favorite thing to point out in administrative hearings and in court hearings is, but your client only makes two or three formulations. How is it possible that all of their patients only need two or three? And I said, well, it's not possible. For the patients that don't benefit...
24:26 Speaker 03 From those two or three formulations, they're going other places. Let me point out this pharmacy that makes two or three different kinds of formulations, and they're just as busy as my client. Let's point out this one that makes another two or three. And so because my clients aren't manufacturers, they can't produce everything for everyone. So if someone comes to them and says, I need this particular mixture, this particular formulation, our clients often say, you know what, that's not something that we're set up to do. It's very expensive for us to reevaluate a new formulation. But I happen to have a colleague in another state, in another location that's licensed here, that does make that formulation.
25:09 Speaker 03 Those phone calls and those referrals happen every day.
25:12 Speaker 02 Well, and the other thing that the judge in the Willow case seemed to recognize is that these are based on the judgment of a prescriber. That often gets left out of this conversation. It gets left out in media reporting, it gets out, left out in what some of the sock puppets say to Congress, there is a prescriber using his or her judgment to determine that an individual patient needs this drug.
25:34 Speaker 03 That's absolutely right, and we lose that. I have to remind administrative agencies and courts all the time, pharmacies don't get to decide.
25:46 Speaker 02 Yeah, nothing, nothing happens in a compounding pharmacy until a script comes in.
25:51 Speaker 03 That's right. And our job, and I do this not just with compounded medications, but anytime I'm defending a pharmacist related to something they've dispensed, our job is not to practice medicine, our job is to practice pharmacy. And that means providing a safety net to potentially dangerous medications, potentially, you know, typographical errors that might lead to something, and helping pay attention to drug-drug interactions that the prescriber of record for prescription A may not know there was a different prescriber for prescription B. Our job is not to veto a prescription, but to provide information to the prescriber if there are concerns about it. But at the end of the day, the person practicing medicine, which is the prescriber, physician,
26:34 Speaker 03 nurse practitioner, PA, they made that decision.
26:37 Speaker 02 Yeah.
26:38 Speaker 03 If you're concerned about their medical judgment, then that's a different person to talk to.
26:44 Speaker 02 Yeah, that's a different sort of discussion. I appreciate your thoughts on that. I want to jump to a couple of other areas of litigation. Let's talk briefly about Florida. So, back during the early, mid-days of the shortage, drugmakers filed lawsuits against a number of compounding pharmacies, mostly in Texas, Tennessee, and Florida, several in the state of Florida. In each of those cases, and correct me, Mark, if you think I get this wrong, this is my layman's reading of those briefs, you could read those briefs from drugmakers and be compelled
27:27 Speaker 02 to think that there was no federal government, that there was no Food, Drug & Cosmetic Act, that there was no FDA, there were only state deceptive practices laws. And the drugmakers were accusing the pharmacies of unauthorized drug manufacturing and deceptive practices. Well, in at least three cases, four cases, in Florida, the drugmakers lost those lawsuits. APC actually filed amicus briefs in a couple of those cases, just trying to make sure that the court understood the proper role of compounding in law and policy. So, the compounding pharmacies prevail, and of course, the drugmakers are now appealing.
28:08 Speaker 02 The courts, I think, I don't know, you may teach me another new word like dicta, but the courts have combined those cases, at least three of those cases, into one on appeal. There's another one, Brooksville, hanging out there, that we wonder might be added to that group. And APC will once again be filing an amicus brief in those cases. Can you talk a little bit about what's at stake and what's going on there, just briefly?
28:35 Speaker 03 Yes, I can. And what happened in Florida and is happening in Texas as well, on a very similar case, they almost mirror each other, is the drug companies have found an obscure part of the law in Florida, it exists also in five other states, that is found not within the Pharmacy Practice Act, not within the Medical Practice Act, but in a separate part of the law that just talks generally about consumer protection. And to oversimplify it, it's a provision that says, hey, as a state, we don't allow entities, whether they be people or businesses, to introduce unapproved drugs into our marketplace.
29:18 Speaker 03 And I know exactly, well, I don't know exactly, but I can speculate with some certainty as to where this comes from. So anybody who knows a little bit about politics knows that your elected people come from all walks of life. There are exterminators, there are nurses, there are sometimes doctors, there are very few pharmacists, but God bless the ones that are there. But everybody is responsible for knowing everything. You've got, in the legislature, committees that write these bills. And the Pharmacy Practice Act, the Medical Practice Acts, those are usually going to be in health committees, those are going to be people who understand health law. But these consumer protection laws usually end up in different places, different committees,
30:01 Speaker 03 where you've got no discussion of health, hardly ever. And I can see someone, and I see this in my daily life, well, in order to protect the consumers, we should make sure that no one sends or tries to sell a drug in our state that's not FDA-approved, because they're all approved, right? Every single one has to be. And the layman just assumes that, and they have no idea. And you know this, and I know this, compounded drugs by definition are not FDA-approved. Most of the over-the-counter medications aren't FDA-approved, they're made pursuant to a monograph, which is simply a recipe that exists in the federal register. And if you follow the recipe, you're allowed to market it. You've got all of these drugs that were made before 1990.
30:45 Speaker 03 Before the Food Drug and Cosmetic Act, and they've been grandfathered in but have never
30:49 Speaker 02 Grandfathered drugs, yeah.
30:50 Speaker 03 FDA approval. So you've got all of these medications out there, over the counter and prescription, that have never been FDA approved, but you try to tell a lawmaker who's sitting on the Consumer Protection Committee that, and their jaws would drop. And so you've got these obscure laws that clearly contradict the Pharmacy Practice Act and the Medical Practice Act in those states. So let's say there was no federal government. Even in Florida, I could say, well, this is impossible to do because the entities that regulate medicine not only allow for this, but they expressly allow for this, which is allowing
31:31 Speaker 03 doctors to write for and pharmacists to dispense certain unapproved medications and for retailers to market OTC medications, many of which have never been FDA approved. And so even if I just took Florida law, I could dispatch with it. But what the drugmakers did was say, the Florida law ought to control, or in these other states, the other states' laws ought to control. And because the Food Drug and Cosmetic Act is not preemptive, there is no express preemption in the Food Drug and Cosmetic Act that says, hey, no matter what we do, we're going to preempt any state law that's contradictory to this.
32:12 Speaker 03 But there is a long case history of, even though those words might not be in there, they mean what they mean.
32:19 Speaker 02 And so that's how the courts in these cases ruled in federal preemption. There's no private right of action by a drugmaker to enforce the Food Drug and Cosmetic Act. So let's fast forward to their appeal. What do you, on what basis are they appealing?
32:36 Speaker 03 Well, I'm a little worried that they're going to appeal based upon a relatively New Fifth Circuit Court of Appeals case.
32:46 Speaker 02 And that's the other one I want to talk with you about. So let's just go right into it. You're talking about the Xylea case, right?
32:51 Speaker 03 Yeah, they intermingled. So Xylea is a drug manufacturer, traditional drug manufacturer, and Wells Pharma is a 503B outsourcing facility. And we're going to talk about something as boring as indomethacin suppositories right now. And what was the case? Xylea makes commercially available indomethacin suppositories at 50 milligrams per dose, if I'm remembering correctly. And Wells Pharma, 503B, compounds 100-milligram suppositories because those are necessary for the patients that, at the institutions and at the prescribers' offices and at the 503A
33:32 Speaker 03 pharmacies, whose doctors have said, hey, this person needs more. And I'm not going to ask the person to insert two suppositories rectally. I'm going to order one, because that's more humane and more friendly, and it's going to cause more compliance. And there's nothing wrong with that. It's not essentially a copy. There's a legitimate medical need. You can absolutely substantiate for these patients. I'm presuming that they needed a higher dose than what Xylea is going to support. And Texas court was asked to review these laws. And they came to the same conclusion. The lower court said, now, the FDA preempts this. If you've got a problem, Xylea, go complain to the FDA.
34:17 Speaker 03 If the 503B is doing something wrong, that's their job to figure it out. It's not even for us to consider. Xylea didn't take that for an answer. They went to the Fifth Circuit Court of Appeals. And very briefly, you've got, and I wrote it in a brief to the Supreme Court for another client, which was, I'm concerned that this judge is using something as low salient as indomethacin suppositories. You are not going to hear Shannon Bream on Fox News Sunday or Nora O'Donnell talk about an indomethacin suppository case.
34:54 Speaker 02 Although that would be fun if they did, yes.
34:56 Speaker 03 It would be fun, but I don't think they can, even they can't make it entertaining.
35:00 Speaker 02 Yeah, right.
35:01 Speaker 03 And so, what the Texas court wants to do, and this is speculation, but I believe it's true.
35:11 Speaker 03 Texas, and what's interesting is Texas doesn't have this problem. Texas isn't one of these six states. But this is a Texas judge, Judge Ho. Judge Ho is a big deal in the Court of Appeals. It is speculated that if President Trump gets another nominee to the Supreme Court, Judge Ho might be that guy. And so he carries a lot of weight, and he's a good jurist. I admire him, he's a good guy. But I worry he's got his eyes focused on a different prize, which is bigger states' rights issues that are more critical than indomethacin suppositories, particularly in Texas. You have the Texas Rangers, in particular, working with Governor Abbott on trying to enforce immigration laws.
35:56 Speaker 03 Traditionally, that has been a role that the courts have said belonged exclusively to the federal police department, namely ICE and border security. And we know this because Arizona tried that during the Obama administration. We would have our law enforcement officers arrest people simply for the crime of entering the country illegally. The Obama administration sued Arizona, and the court said, "No, that's not for local police to determine, that's federal police." And so you can't do that. You can't send your regular agents there.
36:27 Speaker 02 Well, and so you've got Texas with an eye toward this border immigration enforcement sort of thing. You've also got, I mean, is not Mifaprestone potentially at play in this as well? And so a lawsuit about a suppository is suddenly, has the potential to become a three-ring circus?
36:50 Speaker 03 It does, and that's something I tried to get the Supreme Court alerted to. And Wells wants to appeal this Fifth Circuit Court of decision because it's got broad implications on our entire profession. If the Fifth Circuit has said there's a chink in the armor related to the supremacy of the Food Drug and Cosmetic Act, that's a problem because now you can have states do what they want. And so whether it's something unrelated to pharmacy like immigration or gun ownership rights or directly related to pharmacy, which is Mifepristone, RD486, and whether or not
37:31 Speaker 03 a state can regulate that separately from the FDA, those are big deals. And we're already seeing that regardless of your position, pro-life, pro-choice, Mifepristone or not, in my opinion, it's important that the 50 states, the Districts of Columbia and the Territories, all act the same as it relates to our drug supply.
37:54 Speaker 02 And you would think in this, in this particular case, FDA is going to want the same thing. FDA is not going to want preemption shutdown. So it'll be interesting to watch what they do there. We're about to have to wrap up. Bring this back, let's go back to Florida. How does Xyla play in Florida again? If you would put a fine point on that.
38:13 Speaker 03 My concern is the law has changed since the lower courts reviewed these cases in Florida and threw them out. Now there's a Fifth Circuit decision that is newer, and I believe that's one of the reasons why Novo wants to take another run at this. Now, what's nice about the Fifth Circuit is it's not in Florida. Florida is the 11th Circuit. And even though the Fifth Circuit has a new precedent out there, it's only persuasive in the other districts. It's not binding. And so while
38:51 Speaker 03 Wells fights at the Supreme Court level to remove this precedent, and I hope they win. It's only persuasive in the 11th Circuit. The 11th Circuit and the Ninth Circuit, which is the other side of the country that I just talked about, have strong precedent that say, no, no, no. The Food Drug and Cosmetic Act clearly has supreme authority over any state that contradicts it. And I even think if you admit this Fifth Circuit appeal, Judge Ho said, as long as the state's law mirrors the federal law, it's enforceable. Well, I don't necessarily disagree with that, except you've just told me it doesn't mirror federal law. It's different.
39:33 Speaker 03 So where does your mirror analogy come from? And so I think there's a flaw in that argument.
39:40 Speaker 02 Well, it's gonna be really-
39:42 Speaker 03 That's how it relates to Florida, is there's a new piece of case law that Novo can bring to the table that they didn't have a chance to in the lower court.
39:51 Speaker 02 Well, it's gonna be, it's gonna be interesting to watch that one. Well, to watch Xyla and whether Wells, whether the Supreme Court agrees to take the Wells-Xyla case, and then what the implications might be for Florida and for other states. We are out of time. We did not get to talk about some of the shenanigans the drug makers have been pulling with state boards of pharmacy. Letters to state boards of pharmacy that miss state law and policy. They've been meddling a bit in state attempts to regulate 503(b) sourcing to 503(a's). And I think most disturbing to a lot of APC members is the filing of nuisance complaints against particular pharmacies.
40:34 Speaker 02 And we sort of feel like the nuisance complaints, that the drug makers not, the pharmacy's going to be found innocent of those, but they have to lawyer up to defend themselves against these claims. So maybe we'll have you back sometime to talk about those, and there's plenty more to talk about as well. Thanks, Mark, for being with us, and thanks for your perspective. We appreciate all you do for the pharmacy compounding industry.
40:57 Speaker 03 I appreciate that. Happy to be back anytime.
41:01 Speaker 02 Andrew, back to you.
41:02 Speaker 01 Thank you, Scott. Thank you, Mark. We know you're a busy guy. We really appreciate your time. Before we play the end music here, something I want to point out. If you are a compounding pharmacist, or you prescribe compounded medication, APC is almost certainly helping you and helping your patients. I'm not going to go through everything we do, but I will say that APC is the biggest, and in a good way, the loudest trade association for the compounding profession. So if you're not a member of APC, you really ought to be. We're working for you. We'd love to have you onboard. Just head over to a4pc.org. Check us out. All right, now we can play that end music. Thanks for listening.
Previous NSAIDs: Everything and Then Some | Pain Pod Next Data to Impact: Nested Knowledge & the 31-Day Pharmacist Challenge | TWIRx Page updated November 14, 2026 · transcript and summary are machine-generated